Ustekinumab‑Aauz Suppliers & Bulk Manufacturers
Available Forms: Subcutaneous injection, Intravenous infusion
Available Strengths: 45 mg or 90 mg
Reference Brands: Stelara(US & EU); Otulfi (ustekinumab-srlf) is a biosimilar of Stelara
Category:
Biosimilars
Ustekinumab-aauz blocks interleukins 12 and 23, reducing inflammation and immune response. It effectively treats psoriasis, psoriatic arthritis, and Crohn's disease. Benefits include sustained symptom relief, improved skin and joint health, and enhanced quality of life through targeted therapy when administered under medical supervision.
Ustekinumab‑aauz is available in Subcutaneous injection, Intravenous infusion
and strengths such as 45 mg or 90 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ustekinumab‑aauz is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ustekinumab‑aauz can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ustekinumab-aauz is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality compliant with GMP and MDR standards. In the US, FDA approval requires comprehensive clinical trial data and safety validation. In the EU, CE marking certifies conformity with MDR. These products undergo validation, stability testing, and audits, with detailed documentation including safety profiles, clinical efficacy data, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to safe, effective biologic therapies globally, supporting management of psoriasis, psoriatic arthritis, and Crohn’s disease for optimal patient outcomes.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing